680 filings
Page 25 of 34
6-K
s6kaqqyp5taf
4 May 16
RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
12:00am
6-K
bk83zvm11
25 Apr 16
RedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit
12:00am
6-K
cijk zlb6
20 Apr 16
Current report (foreign)
12:00am
6-K
3x0gzpmrwn83kd2y de
19 Apr 16
RedHill Biopharma to Participate in the FBR & Co. Healthcare Series Focused on Infectious Diseases
12:00am
6-K
uen2z j8f
18 Apr 16
RedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
12:00am
6-K
wur4b
13 Apr 16
RedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016
12:00am
6-K
r4qte3p
11 Apr 16
Current report (foreign)
12:00am
6-K
qp7jxot981pmcbyx4kj
31 Mar 16
RedHill Biopharma Announces Interim Results from Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis
12:00am
6-K
661sre40483rixa
29 Mar 16
RedHill Biopharma and IntelGenx Announce RIZAPORT™ Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories
12:00am
6-K
ddy3zqpuuazhj3bva
28 Mar 16
RedHill Biopharma to Present at Bio-Europe Spring 2016 Conference
12:00am
6-K
wdthfs 9ib6qrv1pg
10 Mar 16
RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer
12:00am
6-K
7xzht 28ms22avhwpq
9 Mar 16
RedHill Biopharma to Present at the 28th Annual ROTH Conference
12:00am
6-K
xvxfb1a5og91p
8 Mar 16
RedHill Biopharma Reports Successful Final Results of Phase III Study With RHB-105 for H. pylori Infection
12:00am
6-K
zvyga4 hy39cyt
1 Mar 16
RedHill Biopharma Provides 2016 R&D Update
12:00am
6-K
dwd4 ink4
25 Feb 16
RedHill Biopharma Reports 2015 Fourth Quarter and Full-Year Financial Results
12:00am
6-K
q7u026634k 906ae
18 Feb 16
RedHill Biopharma to Host 2015 Fourth Quarter and Year-End Financial Results Conference Call on February 25, 2016
12:00am
6-K
jpzcxy
18 Feb 16
RedHill Biopharma Announces Notice of Allowance for U.S. Patent Covering RIZAPORT™ for Migraines
12:00am
6-K
rb93ydqavpsap
17 Feb 16
RedHill Biopharma Appoints Dr. June S. Almenoff and Ms. Theresa M. Stevens to Advisory Board
12:00am
6-K
rv8g7t
16 Feb 16
Current report (foreign)
12:00am
6-K
pf1n4qsi2u0or1
11 Feb 16
RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol
12:00am